Supplementary Table 2. Meta-analysis results of the associations between the expression of FUT8 and survival of tumors.

| Tumor Source                          | Reference          | Subgroup                  | Survival | HR & 95% CI          | Analysis |
|---------------------------------------|--------------------|---------------------------|----------|----------------------|----------|
| Non-Small Cell Lung Cancer            | Honma 2015         |                           | OS       | 1.93 (1.07-3.47)     | Univariate |
|                                       |                    | TNM pStage I              | OS       | 1.81 (1.01-3.25)     | Multivariate |
|                                       | Chen 2012          |                           | OS       | 2.55 (1.08-6.03)     | Univariate |
|                                       |                    |                           | OS       | 2.29 (1.51-3.48)     | Univariate |
|                                       |                    |                           | OS       | 2.32 (1.51-3.58)     | Univariate |
|                                       | Wu 2019            |                           | DFS      | 2.41 (1.59-3.66)     | Univariate |
|                                       |                    |                           | DFS      | 2.68 (1.62-3.89)     | Multivariate |
|                                       | Park 2019          |                           | DFS      | 2.97 (1.09-8.12)     | Univariate |
|                                       |                    |                           | DFS      | 1.87 (0.77-4.51)     | Univariate |
| Breast Cancer                         | Yue 2016           |                           | OS       | 2.49 (1.15-5.37)     | Univariate |
|                                       |                    |                           | DFS      | 1.91 (1.01-3.61)     | Univariate |
| Diffuse Large B Cell Lymphoma         | Xiao 2008          | Age (≥50 years)           | OS       | 1.76 (1.3-2.38)      | Univariate |
|                                       |                    | Ann Arbor Stage I-III     | OS       | 1.42 (1.02-1.98)     | Univariate |
|                                       |                    |                           | OS       | 1.87 (1.24-2.81)     | Univariate |
| Gastric Cancer                        | Tan 2018           | Gender (Male)             | OS       | 0.60 (0.40-0.91)     | Univariate |
|                                       |                    | TNM Stage I-III           | OS       | 0.59 (0.35-0.99)     | Univariate |
|                                       |                    | Lauren_Intestinal         | OS       | 0.53 (0.31-0.90)     | Univariate |
|                                       |                    |                           | OS       | 0.50 (0.28-0.90)     | Univariate |
| Colorectal Cancer                     | Noda 2018          | TNM Stage II-III & p53 (-)| DFS     | 0.28 (0.1-0.76)      | Univariate |
|                                       |                    | TNM Stage II-III & p53 (+)| DFS     | 1.25 (0.27-5.88)     | Univariate |
|                                       |                    | TNM Stage II-III & p53 (wild-type)| DFS | 0.72 (0.41-1.28) | Univariate |
|                                       |                    | TNM Stage II-III & p53 (mutant)| DFS | 1.02 (0.64-1.64) | Univariate |
| Pancreatic Ductal Adenocarcinoma Glioma | Tada 2019        | TNM Stage II-III & p53 (-)| DFS     | 0.31 (0.11-0.88)     | Multivariate |
|                                       |                    | RFS                       | RFS      | 1.77 (1.06-2.95)     | Univariate |
|                                       |                    | Gender (Female)           | OS       | 1.49 (1.13-1.96)     | Univariate |

HR, hazard ratio; OS, overall survival; DFS, disease-free survival.